| Website | promethera.com |
| Category | BioTech |
| Phone | +32 (0)10 39 43 00 |
| contact@promether... | |
| Employees |
| TOTAL | $38.8M |
| FUNDING TOTAL | $38.8M |
| Series A, 2/10 Vesalius Biocapital Partners Société Régionale d'Investissement de Wallonie Life Sciences Partners | $7.3M |
| Series B, 3/12 Boehringer Ingelheim Venture Fund Shire Mitsui Global Investment | €23.6M |
Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.
Promethera® Biosciences’ mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.
Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):
